228 related articles for article (PubMed ID: 27036506)
1. Trends in Use of Medications for Smoking Cessation in Medicare, 2007-2012.
Jarlenski M; Hyon Baik S; Zhang Y
Am J Prev Med; 2016 Sep; 51(3):301-8. PubMed ID: 27036506
[TBL] [Abstract][Full Text] [Related]
2. Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua.
Lutz MA; Lovato P; Cuesta G
Hosp Pract (1995); 2012 Feb; 40(1):35-43. PubMed ID: 22406881
[TBL] [Abstract][Full Text] [Related]
3. Characterising the use of varenicline: an analysis of the Australian dispensing claims data.
Gobarani RK; Ilomäki J; Wood S; Abramson MJ; Bonevski B; George J
Addiction; 2022 Oct; 117(10):2683-2694. PubMed ID: 35603915
[TBL] [Abstract][Full Text] [Related]
4. Did the introduction of varenicline in England substitute for or add to the use of other smoking cessation medications?
Kotz D; Fidler JA; West R
Nicotine Tob Res; 2011 Sep; 13(9):793-9. PubMed ID: 21543548
[TBL] [Abstract][Full Text] [Related]
5. Influence of smoking cessation drugs on blood pressure and heart rate in patients with cardiovascular disease or high risk score: real life setting.
Silva AP; Scholz J; Abe TO; Pinheiro GG; Gaya PV; Pereira AC; Santos PC
BMC Cardiovasc Disord; 2016 Jan; 16():2. PubMed ID: 26728720
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.
Lutz MA; Lovato P; Cuesta G
Hosp Pract (1995); 2012 Feb; 40(1):24-34. PubMed ID: 22406880
[TBL] [Abstract][Full Text] [Related]
7. Trends in utilization of smoking cessation agents before and after the passage of FDA boxed warning in the United States.
Shah D; Shah A; Tan X; Sambamoorthi U
Drug Alcohol Depend; 2017 Aug; 177():187-193. PubMed ID: 28605678
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular and mortality risks in older Medicare patients treated with varenicline or bupropion for smoking cessation: an observational cohort study.
Graham DJ; By K; McKean S; Mosholder A; Kornegay C; Racoosin JA; Young J; Levenson M; MaCurdy TE; Worrall C; Kelman JA
Pharmacoepidemiol Drug Saf; 2014 Nov; 23(11):1205-12. PubMed ID: 25044169
[TBL] [Abstract][Full Text] [Related]
9. Comparative Safety of Smoking Cessation Pharmacotherapies During a Government-Sponsored Reimbursement Program.
Carney G; Maclure M; Malfair S; Bassett K; Wright JM; Dormuth CR
Nicotine Tob Res; 2021 Jan; 23(2):302-309. PubMed ID: 32484873
[TBL] [Abstract][Full Text] [Related]
10. Use of stop-smoking medications in the United States before and after the introduction of varenicline.
Kasza KA; Cummings KM; Carpenter MJ; Cornelius ME; Hyland AJ; Fong GT
Addiction; 2015 Feb; 110(2):346-55. PubMed ID: 25331778
[TBL] [Abstract][Full Text] [Related]
11. The Adverse Effects and Treatment Results of Smoking Cessation Pharmacotherapy During Fasting/Non-Fasting State.
Iliaz S; Tural Onur S; Uysal MA; Chousein EGU; Tanriverdi E; Bagci BA; Bahadir A; Hattatoglu DG; Ortakoylu MG; Yurt S
Subst Use Misuse; 2017 Jul; 52(8):969-973. PubMed ID: 28296573
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial.
Benowitz NL; Pipe A; West R; Hays JT; Tonstad S; McRae T; Lawrence D; St Aubin L; Anthenelli RM
JAMA Intern Med; 2018 May; 178(5):622-631. PubMed ID: 29630702
[TBL] [Abstract][Full Text] [Related]
13. Comparative Effectiveness of Smoking Cessation Medications to Attenuate Weight Gain Following Cessation.
Yang M; Chen H; Johnson ML; Essien EJ; Peters RJ; Wang X; Abughosh S
Subst Use Misuse; 2016; 51(5):586-97. PubMed ID: 27007975
[TBL] [Abstract][Full Text] [Related]
14. Systematic review and meta-analysis of combination therapy for smoking cessation.
Shah SD; Wilken LA; Winkler SR; Lin SJ
J Am Pharm Assoc (2003); 2008; 48(5):659-65. PubMed ID: 18826906
[TBL] [Abstract][Full Text] [Related]
15. Empowering smokers with a web-assisted tobacco intervention to use prescription smoking cessation medications: a feasibility trial.
Selby P; Hussain S; Voci S; Zawertailo L
Implement Sci; 2015 Oct; 10():139. PubMed ID: 26429100
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Driving Factors of Willingness to Use and Willingness to Pay for Existing Pharmacological Smoking Cessation Aids Among Young and Middle-Aged Adults in Germany.
Aumann I; Treskova M; Hagemann N; von der Schulenburg JM
Appl Health Econ Health Policy; 2016 Aug; 14(4):441-452. PubMed ID: 27021824
[TBL] [Abstract][Full Text] [Related]
17. Medicaid Coverage of Smoking Cessation Counseling and Medication Is Underutilized for Pregnant Women.
Scheuermann TS; Richter KP; Jacobson LT; Shireman TI
Nicotine Tob Res; 2017 May; 19(5):656-659. PubMed ID: 28403462
[TBL] [Abstract][Full Text] [Related]
18. Flexible, dual-form nicotine replacement therapy or varenicline in comparison with nicotine patch for smoking cessation: a randomized controlled trial.
Tulloch HE; Pipe AL; Els C; Clyde MJ; Reid RD
BMC Med; 2016 Jun; 14():80. PubMed ID: 27233840
[TBL] [Abstract][Full Text] [Related]
19. Effects of aging on the effectiveness of smoking cessation medication.
Scholz J; Santos PC; Buzo CG; Lopes NH; Abe TO; Gaya PV; Pierri H; Amorim C; Pereira AC
Oncotarget; 2016 May; 7(21):30032-6. PubMed ID: 27166253
[TBL] [Abstract][Full Text] [Related]
20. Utilization and effectiveness of pharmacotherapy for tobacco use following admission for exacerbation of COPD.
Melzer AC; Feemster LC; Collins MP; Au DH
J Hosp Med; 2016 Apr; 11(4):257-63. PubMed ID: 26663891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
